AU5771500A - Catalytically active recombinant memapsin and methods of use thereof - Google Patents

Catalytically active recombinant memapsin and methods of use thereof Download PDF

Info

Publication number
AU5771500A
AU5771500A AU57715/00A AU5771500A AU5771500A AU 5771500 A AU5771500 A AU 5771500A AU 57715/00 A AU57715/00 A AU 57715/00A AU 5771500 A AU5771500 A AU 5771500A AU 5771500 A AU5771500 A AU 5771500A
Authority
AU
Australia
Prior art keywords
memapsin
substrate
inhibitors
seq
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57715/00A
Other languages
English (en)
Inventor
Gerald Koelsch
Xin-Li Lin
Jordan J. N. Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU5771500A publication Critical patent/AU5771500A/en
Priority to AU2004202059A priority Critical patent/AU2004202059A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU57715/00A 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof Abandoned AU5771500A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004202059A AU2004202059A1 (en) 1999-06-28 2004-05-14 Catalytically active recombinant memapsin and methods of use thereof

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US14136399P 1999-06-28 1999-06-28
US60141363 1999-06-28
US16806099P 1999-11-30 1999-11-30
US60168060 1999-11-30
US17783600P 2000-01-25 2000-01-25
US60177836 2000-01-25
US17836800P 2000-01-27 2000-01-27
US60178368 2000-01-27
US21029200P 2000-06-08 2000-06-08
US60210292 2000-06-08
PCT/US2000/017661 WO2001000663A2 (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004202059A Division AU2004202059A1 (en) 1999-06-28 2004-05-14 Catalytically active recombinant memapsin and methods of use thereof

Publications (1)

Publication Number Publication Date
AU5771500A true AU5771500A (en) 2001-01-31

Family

ID=27538142

Family Applications (2)

Application Number Title Priority Date Filing Date
AU57715/00A Abandoned AU5771500A (en) 1999-06-28 2000-06-27 Catalytically active recombinant memapsin and methods of use thereof
AU57735/00A Abandoned AU5773500A (en) 1999-06-28 2000-06-27 Inhibitors of memapsin 2 and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU57735/00A Abandoned AU5773500A (en) 1999-06-28 2000-06-27 Inhibitors of memapsin 2 and use thereof

Country Status (9)

Country Link
US (7) US6545127B1 (cg-RX-API-DMAC7.html)
EP (2) EP1194449B1 (cg-RX-API-DMAC7.html)
JP (2) JP4484410B2 (cg-RX-API-DMAC7.html)
CN (1) CN1379819A (cg-RX-API-DMAC7.html)
AT (1) ATE482233T1 (cg-RX-API-DMAC7.html)
AU (2) AU5771500A (cg-RX-API-DMAC7.html)
CA (2) CA2374346C (cg-RX-API-DMAC7.html)
DE (1) DE60045005D1 (cg-RX-API-DMAC7.html)
WO (2) WO2001000663A2 (cg-RX-API-DMAC7.html)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
ES2318902T3 (es) * 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
EP1194449B1 (en) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
GB9924957D0 (en) * 1999-10-21 1999-12-22 Smithkline Beecham Plc Novel treatment
GB9925136D0 (en) * 1999-10-22 1999-12-22 Smithkline Beecham Plc Novel treatment
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
AU779875B2 (en) * 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
DK1255769T3 (da) 2000-01-25 2007-09-03 Oklahoma Med Res Found Universel procedure til genfoldning af rekombinante proteiner
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2410898A1 (en) * 2000-07-19 2002-01-24 Pharmacia & Upjohn Company Substrates and assays for .beta.-secretase activity
WO2002025276A1 (en) * 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
US7806980B2 (en) * 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US7601528B1 (en) * 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1233021A3 (en) * 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
EP1377664A2 (en) * 2001-02-23 2004-01-07 DSM IP Assets B.V. Genes encoding proteolytic enzymes from aspargilli
US7384773B1 (en) 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7524668B1 (en) 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
JP2004535424A (ja) * 2001-06-11 2004-11-25 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な置換アミノアルコール
CA2452039A1 (en) 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
EP1409660A2 (en) * 2001-07-26 2004-04-21 Astex Technology Limited Crystal structure of beta-site app cleaving enzyme (bace) and use thereof
US7186539B1 (en) * 2001-08-31 2007-03-06 Pharmacia & Upjohn Company Method for refolding enzymes
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
EP1448218A4 (en) * 2001-10-23 2009-01-14 Oklahoma Med Res Found BETA SECRETASE INHIBITORS AND METHOD OF USE
WO2003040393A2 (en) * 2001-11-06 2003-05-15 Decode Genetics Ehf. Nucleic acids encoding proteases
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US7273743B2 (en) 2002-02-21 2007-09-25 Elan Pharmaceuticals, Inc. Modified BACE
KR101011657B1 (ko) 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US7205336B2 (en) 2002-05-17 2007-04-17 Merck & Co., Inc. β-secretase inhibitors
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
US6746303B2 (en) 2002-05-31 2004-06-08 Mattel, Inc. Flexible toy figure with wire armature
AU2003251344A1 (en) * 2002-07-26 2004-02-16 Astex Technology Limited Crystal structure of beta-site app-cleaving enzyme (bace) mutants and uses thereof
US20050074456A1 (en) * 2002-12-04 2005-04-07 Marcus Ballinger Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
EP1583750B1 (en) 2003-01-07 2013-02-27 Merck Sharp & Dohme Corp. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
WO2004099402A1 (en) 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. Glycosylation variants of bace
JP2007516207A (ja) 2003-06-30 2007-06-21 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療のためのN−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
JP2007522088A (ja) 2003-07-01 2007-08-09 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療用フェニルカルボン酸ベータセクレターゼ阻害剤
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
FR2860796B1 (fr) * 2003-10-14 2006-02-10 Centre Nat Rech Scient Procede de dissociation de la molecule d'hemoglobine extracellulaire d'arenicola marina, chaines proteiques constituant ladite molecule et sequences nucleotidiques codant pour lesdites chaines proteiques
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20060019368A1 (en) * 2004-07-20 2006-01-26 Marcus Ballinger Constructs for homogenously processed preparations of beta site APP-cleaving enzyme
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
CA2603404A1 (en) 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
WO2007021886A2 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
EP1923388A4 (en) 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NEURONAL CELL PROTECTIVE AGENT AND THERAPEUTIC AGENT FOR SLEEP DISORDERS
WO2007029587A1 (ja) 2005-09-05 2007-03-15 Dainippon Sumitomo Pharma Co., Ltd. βセクレターゼ阻害剤
WO2007081534A2 (en) * 2005-12-22 2007-07-19 Pfizer Products Inc Method of producing catalytically active bace2 enzymes
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
JP5410278B2 (ja) 2007-06-22 2014-02-05 良明 木曽 βセクレターゼ阻害活性を有する新規化合物
JP5450407B2 (ja) 2007-07-06 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法
CN101868457B (zh) * 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009155609A1 (en) 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
AU2011326564A1 (en) 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
SG11201407796YA (en) 2012-05-30 2014-12-30 Comentis Inc Chromane compounds
WO2014061676A1 (ja) 2012-10-16 2014-04-24 武田薬品工業株式会社 複素環化合物
EA029056B1 (ru) 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
US9624184B2 (en) 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
WO2015190613A1 (en) 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Radiolabeled compounds
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
WO2017040808A1 (en) * 2015-09-03 2017-03-09 Contact Effect, Inc. Management of tenant locations in multi-tenant environments
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US9919021B2 (en) * 2016-04-15 2018-03-20 Ibet—Instituto De Biologia Experimental E Tecnológica Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP3774800B1 (en) 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN108588040B (zh) * 2018-06-08 2021-06-15 中国医学科学院病原生物学研究所 重组MtMetRS、其晶体及它们在制备抗结核药物中的应用
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
WO2021048822A1 (en) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
JP2021183586A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
JP2021183587A (ja) 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
US20230313196A1 (en) * 2020-07-23 2023-10-05 John Mansell Compositions and methods for treating pain and anxiety disorders
TW202302100A (zh) 2021-03-12 2023-01-16 日商武田藥品工業股份有限公司 食慾激素2受體促效劑於治療食慾激素介導之疾病或病症之用途
US20250145947A1 (en) 2021-11-17 2025-05-08 Takeda Pharmaceutical Company Limited Cell production method
US20250250230A1 (en) 2022-04-12 2025-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
PE20251923A1 (es) 2022-10-31 2025-08-05 Takeda Pharmaceutical Co Limited Compuesto heterociclico
WO2024116086A1 (en) 2022-11-30 2024-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US72050A (en) * 1867-12-10 Improvement in horse hiy-foeks
US55459A (en) * 1866-06-12 Improvement in artificial legs
US159991A (en) * 1875-02-16 Improvement in shoe-tips
US81634A (en) * 1868-09-01 Improved kailway-switch
US111365A (en) * 1871-01-31 Improvement in combined rocking sofas and bedsteads
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4985544A (en) 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5221607A (en) 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
US5252463A (en) 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5200339A (en) 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5187074A (en) 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
US5192668A (en) 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993008184A1 (en) 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL105793A0 (en) 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
KR960702518A (ko) 1993-05-17 1996-04-27 린다 에스, 스티븐슨 Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids)
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995010281A1 (en) 1993-10-13 1995-04-20 Merck & Co., Inc. Combination therapy for hiv infection
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5476874A (en) 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6329163B1 (en) 1995-06-07 2001-12-11 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase inhibition
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5978740A (en) 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
WO1997027296A1 (en) 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
US5846978A (en) 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
EP0812916A3 (en) 1996-06-14 1998-12-09 Smithkline Beecham Corporation Cathepsin k gene
DE19641180A1 (de) 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998015828A1 (en) 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
WO1998021589A1 (en) 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
US6207710B1 (en) * 1996-11-22 2001-03-27 Elan Pharmaceuticals, Inc. Compounds for inhibiting β-amyloid peptide release and/or its synthesis
WO1998026059A1 (en) 1996-12-11 1998-06-18 Athena Neurosciences, Inc. Beta-secretase isolated from human 293 cells
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6077682A (en) 1998-03-19 2000-06-20 University Of Medicine And Dentistry Of New Jersey Methods of identifying inhibitors of sensor histidine kinases through rational drug design
WO1999051752A1 (en) 1998-03-31 1999-10-14 Chugai Seiyaku Kabushiki Kaisha CELL LINE NOT EXPRESSING β-SECRETASE ACTIVITY
KR20010052499A (ko) 1998-06-05 2001-06-25 아방티 파르마 소시에테 아노님 베타-시크리타제형 활성을 지닌 폴리펩타이드
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
WO2000058479A1 (en) * 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
JP2003502342A (ja) 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド ベータ−セクレターゼのスタチン誘導テトラペプチド阻害剤
EP1496124A1 (en) 1999-06-28 2005-01-12 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
EP1194449B1 (en) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
DK1224297T3 (da) 1999-09-23 2009-09-07 Pharmacia & Upjohn Co Llc Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf
US6361975B1 (en) * 1999-11-16 2002-03-26 Smithkline Beecham Corporation Mouse aspartic secretase-2(mASP-2)
US6291223B1 (en) * 1999-11-23 2001-09-18 Smithkline Beecham Corporation Mouse aspartic secretase-1 (mASP1)
DK1255769T3 (da) * 2000-01-25 2007-09-03 Oklahoma Med Res Found Universel procedure til genfoldning af rekombinante proteiner
US20020072060A1 (en) 2000-07-19 2002-06-13 Getts Robert C. Methods for detecting and assaying nucleic acid sequences
AU2001252958A1 (en) 2000-03-23 2001-10-03 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
WO2002025276A1 (en) 2000-09-22 2002-03-28 Wyeth Crystal structure of bace and uses thereof
US20020157122A1 (en) * 2000-10-27 2002-10-24 Wong Philip C. Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
EP1404718A2 (en) 2000-12-28 2004-04-07 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
WO2007021886A2 (en) 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease

Also Published As

Publication number Publication date
EP1194449B1 (en) 2010-09-22
US6545127B1 (en) 2003-04-08
US20040220079A1 (en) 2004-11-04
WO2001000665A2 (en) 2001-01-04
US20040167075A1 (en) 2004-08-26
US7829669B2 (en) 2010-11-09
US20020115600A1 (en) 2002-08-22
AU5773500A (en) 2001-01-31
US7678760B2 (en) 2010-03-16
CA2374610A1 (en) 2001-01-04
ATE482233T1 (de) 2010-10-15
WO2001000663A2 (en) 2001-01-04
JP2003503072A (ja) 2003-01-28
EP1194449A2 (en) 2002-04-10
WO2001000665A9 (en) 2002-07-25
WO2001000663A3 (en) 2001-10-04
US7244708B2 (en) 2007-07-17
CA2374346A1 (en) 2001-01-04
WO2001000665A3 (en) 2001-09-27
US20080112946A1 (en) 2008-05-15
DE60045005D1 (de) 2010-11-04
EP1196609A2 (en) 2002-04-17
JP5138851B2 (ja) 2013-02-06
US20020164760A1 (en) 2002-11-07
JP2003506322A (ja) 2003-02-18
JP4484410B2 (ja) 2010-06-16
CN1379819A (zh) 2002-11-13
US20080021196A1 (en) 2008-01-24
CA2374346C (en) 2010-06-22

Similar Documents

Publication Publication Date Title
US7244708B2 (en) Inhibitors of memapsin 2 and use thereof
US6274336B1 (en) Method of inhibiting cathepsin K
Patel et al. Apo and inhibitor complex structures of BACE (β-secretase)
AU2002239727C1 (en) Inhibitors of memapsin 2 and use thereof
Abad‐Zapatero et al. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents
AU2002239727A1 (en) Inhibitors of memapsin 2 and use thereof
JP2011093907A (ja) 新規ハチ毒液ポリペプチドおよびその使用の方法
US20020049303A1 (en) Catalytically active recombinant memapsin and methods of use thereof
JPH08508464A (ja) カテプシンdはアルツハイマー病におけるアミロイド生成プロテアーゼである
EP1496124A1 (en) Catalytically active recombinant memapsin and methods of use thereof
AU2004202058B2 (en) Inhibitors of memapsin 2 and use thereof
AU2004202059A1 (en) Catalytically active recombinant memapsin and methods of use thereof
JP2000505457A (ja) アポペインの結晶構造及びその使用
JP2004337001A (ja) 新規なセリンプロテアーゼmp493
CA2175564A1 (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted